A ngina pectoris is the most common manifestation of coronary heart disease, which is the major cause of death in Europe and North America. 1 2 The symptoms and the morbidity related to angina lead to significant health care expenditure. 3 Aspirin, angiotensin converting enzyme (ACE) inhibitors, and statins have been shown to reduce the risk of cardiovascular events in patients with coronary disease. [4] [5] [6] [7] [8] Recently, the IONA (impact of nicorandil in angina) trial became the first study to demonstrate a similar effect with a specific anti-anginal agent. 9 The properties of nicorandil have been described elsewhere. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] The objective of the current analysis was to investigate whether or not the results of IONA were consistent across subgroups.
METHODS
The design of IONA has been reported elsewhere. 21 Briefly, patients with a history of angina were recruited from hospital and primary care centres in the UK. Standard background anti-anginal treatment was to be optimal therapy as judged by the investigator for the individual patient. Patients were randomised to a double blind comparison of nicorandil (10 mg twice daily for two weeks and 20 mg twice daily thereafter) and placebo. High risk men over 45 years, or women over 55 years, were recruited. Follow up was for an average of 1.6 years (range 1-3 years). The primary end point of the study was the composite of coronary heart disease death, non-fatal myocardial infarction, or unplanned hospitalisation for cardiac chest pain. 21 Risk factor subgroups were defined as history of diabetes, hypertension, myocardial infarction, coronary revascularisation (all yes/no); current smoking status (yes/no), age (, 65, 65-70 and . 70 years), sex; background medication with b blockers, calcium channel blockers, long acting nitrates, diuretics, ACE inhibitors, aspirin, statins (all yes/no); numbers of anti-anginal medications being taken (one, two, or three drugs from b blockers, calcium channel blockers, or long acting nitrates). Baseline anginal severity was assessed using the Canadian Cardiovascular Society (CCS) functional status questionnaire with three groupings (I, II, and III + IV). A subgroup analysis was conducted using the 18 month risk of a primary end point calculated from a model which had been fitted to the placebo group using age, systolic blood pressure, heart rate, body mass index, sex, CCS functional status, smoking status, and histories of hypertension, diabetes, left ventricular hypertrophy, and left ventricular function. All analyses were conducted on the intentionto-treat principle and were based on the log rank test and Cox regression analysis as appropriate, including a test of homogeneity of the treatment effect across levels of subgroups.
Patients provided written informed consent and the study complied with the Declaration of Helsinki and was approved by the multi-centre research ethics committees of the UK.
RESULTS
In the trial, 2565 patients were randomised to nicorandil and 2561 to placebo. Overall, nicorandil reduced the incidence of the primary end point from 15.5% to 13.1% (hazard ratio (HR) 0.83, 95% confidence interval (CI) 0.72 to 0.97; p = 0.014). 8 The event rates and risk reduction were similar in patients recruited in general practice and in hospitals (data not shown). Although evidence of benefit is not established statistically in all subgroups, all point estimates of hazard ratios lie on, or to the left, of unity and none of the tests for interaction achieve significance. There is consistency of risk reduction across the tertiles of baseline risk with the number needed to treat (NNT) for 18 months in the three subgroups being respectively 28, 46 and 63 for the high, medium, and low risk groups.
Abbreviations: ACE, angiotensin converting enzyme; CCS, Canadian Cardiovascular Society; IONA, impact of nicorandil in angina; NNT, number needed to treat Estimated hazard ratios and 95% CI for subgroups defined by background medication risk factors analysed on the basis of the primary end point; p values are for tests of homogeneity of therapy effect. The numbers tabulated are the numbers of (subjects with events)/(total number of subjects) for the placebo and nicorandil groups.
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DISCUSSION
The subgroup analyses provide no significant evidence of any qualitative or quantitative interactions between nicorandil treatment benefit and subgroup status. The effect of nicorandil on top of nitrates adds support to the argument that the mechanism of benefit is other than the nitrate properties of nicorandil and plausibly caused by its potassium channel opening activity. The hazard ratio for treatment benefit was at least as great in subjects receiving three antianginal medications as it was in those receiving one or two medications. A similarly consistent result was achieved across the categories of the CCS functional status questionnaire. Subjects taking higher numbers of anti-anginal medications, or with higher CCS functional status scores, were at particularly high risk. A reduction in relative risk that is independent of baseline risk suggests that treatment of those at highest risk will provide the greatest absolute risk reduction and possibly be the most cost effective. Our results suggest that treating subjects in the highest third of risk will prevent more than twice the number of events compared to the treatment of subjects in the lowest third. However, even in the lowest third of the risk spectrum the NNT is 63, a not unimpressive result for a relatively short period of treatment (1.6 years).
Weaknesses of the analyses that were conducted are primarily caused by the reduced power associated with the important but modest overall risk reduction. Despite this fact, the consistency of benefit across all subgroups supports the view that the overall results of the study in terms of a 17% relative reduction for the primary end point can be applied to a wide range of subjects with coronary disease who suffer from angina pectoris.
Current guidelines place b blockers as the first line treatment for the medical management of angina pectoris. This is probably because, in addition to being effective antianginal agents, they also have an impressive record in reducing major coronary events across a wide spectrum of coronary heart disease, although this has never been tested in an appropriately powered trial in stable angina. In contrast, calcium channel blockers and then long acting nitrates, which are added in or substituted in cases of inadequate efficacy or intolerance to b blockers, have not been shown to have cardioprotective effects in coronary heart disease. Therefore, it would appear that IONA has two important messages for clinical practice. Firstly, in this group of patients with established coronary heart disease, nicorandil may be added to statins, antiplatelet agents, and ACE inhibitors as a member of a class of treatments that prevent major clinical events. Secondly, the secondary prevention properties established in IONA, combined with the already known antianginal properties of nicorandil, suggests that nicorandil should be considered at an earlier stage in the treatment of angina ahead of calcium channel blockers and nitrates.
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APPENDIX: IONA STUDY GROUP
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Ingenix Pharmaceutical Services: Ms V Diment (Project Manager) Figure 3 Hazard ratios for treatment effect and 95% CI based on the primary end point for subgroups defined by tertiles of baseline 18 month risk of a primary end point; p value is for test of homogeneity of magnitude treatment across subgroups. NNT denotes the number of subjects that have to be initiated on treatment to prevent one subject having a primary end point. A transoesophageal echocardiogram showed grade III mitral valve regurgitation secondary to annular dilatation and lateral wall dysfunction. The patient underwent surgery three weeks later. During the operation, the left main stem aneurysm containing multiple thrombi was over-sewn both proximally and distally. The LAD was grafted with the left internal thoracic artery, and intermediate and obtuse marginal arteries were grafted sequentially with a segment of the long saphenous vein. Failure in weaning off from cardiopulmonary bypass, because of the hypoperfusion within the LAD distribution, led to an additional vein graft to the LAD. The mitral valve was repaired using an annuloplasty band. The patient remains clinically asymptomatic; follow up computed tomographic coronary angiography six months later revealed an occluded left main stem and the aneurysm, and patent saphenous vein grafts to the LAD (panel B and C). As there are reports that such patients may also develop extracardiac aneurysms, she underwent a magnetic resonance imaging scan of head, thorax, and abdomen, which did not show any pathology.
IMAGES IN CARDIOLOGY
Aneurysms of the left main coronary artery occur in 0.1% of adults. Only a few descriptions exist of a surgically treated aneurysm of the left main coronary artery. In this case, a direct approach was undertaken to close the aneurysm, and this was combined with mitral valve repair for ischaemic mitral regurgitation.
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